Optimization of Triptorelin Administration in Children With Central Precocious Puberty and Short Stature

Triptorelin is effective not only in the treatment of CPP but also for children with short stature who exhibit premature sexual development, short PHA or impaired TH. In girls with early menarche, the BA indication can be relaxed to 12.5 or even 13 years, with early triptorelin-GH combination therapy recommended to maximize height potential. For those showing adequate pubertal suppression, triptorelin administration intervals can be extended from 4 to 5 weeks. In cases of insufficient suppression, the interval may need to be shortened to 3 weeks. Individualized triptorelin and GH combination therapy appears to offer superior height outcomes, with careful consideration required for optimal timing and duration of treatment.